Search

Displaying results 5401 - 5410 of 6278 in total
  1. Drug

    Tezosentan

    go.drugbank.com/drugs/DB06558
    Investigational

    Tezosentan was initially developed for vasodilation in patients with acute heart failure but studies have shown that it does not assist in the treatment of dyspnea or prevent cardiovascular events.

  2. Drug

    AAV1-FS344

    go.drugbank.com/drugs/DB17855
    Investigational

    It is being investigated for the treatment of Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and inclusion body myositis.[L46742, L46747, L46752]

  3. Drug

    SRP-9005

    go.drugbank.com/drugs/DB17958
    Investigational

    Developed by the Kurt+Peter Foundation and Sarepta Therapeutics, it is being investigated for the treatment of Limb-girdle muscular dystrophy (LGMD) type 2C/R5.[A260142]

  4. Drug

    SOBI-003

    go.drugbank.com/drugs/DB15451
    Investigational

    It is under investigation in clinical trial NCT03811028 (A Study to Assess the Safety, Tolerability, and Efficacy of Long-term SOBI003 Treatment in Pediatric MPS IIIA Patients).

  5. Drug

    Levilimab

    go.drugbank.com/drugs/DB16387
    Investigational

    Levilimab is under investigation in clinical trial NCT04227366 (Study of the Efficacy and Safety of BCD-089 in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis).

  6. Drug

    Cedazuridine

    go.drugbank.com/drugs/DB15694
    ApprovedInvestigational

    Myelodysplastic syndromes (MDS) are a group of hematopoietic neoplasms that give rise to variable cytopenias progressing to secondary acute myeloid leukemia (sAML), which is invariably fatal if untreated. Hypomethylating agents such as d...

  7. Drug

    FP0011

    go.drugbank.com/drugs/DB05090
    Experimental

    It acts on the presynaptic regulation of glutamate and shows strong neuroprotective properties.

  8. Drug

    Alvocidib

    go.drugbank.com/drugs/DB03496
    Investigational

    It works by inhibiting cyclin-dependent kinases, arresting cell division and causing apoptosis in non-small lung cancer cells.

  9. Drug

    CP-122721

    go.drugbank.com/drugs/DB05421
    Experimental

    CP-122721, neurokinin 1 (NK1) antagonist is developed by Pfizer to treat depression, emesis, and inflammatory diseases including asthma and irritable bowel syndrome.

  10. Drug

    KD7040

    go.drugbank.com/drugs/DB05214
    Investigational

    It is being developed by Kalypsys.